IDEXX Laboratories Inc. ($IDXX) Stock Forecast: Down 0.4% Today

What is IDEXX Laboratories Inc.?

IDEXX Laboratories (IDXX): IDEXX Laboratories is a leading provider of veterinary diagnostics and software solutions, known for its innovative products in the companion animal diagnostics market. Today, the stock experienced a strong bearish movement.

Why is IDEXX Laboratories Inc. going down?

IDXX stock is down 0.4% on May 6, 2026 14:41

• Despite reporting strong financial results for Q1 2026 and raising its full-year outlook, concerns about the modest decline in U.S. clinical visits may have impacted future revenue growth potential for IDEXX Laboratories.
• The transition in leadership could have introduced uncertainty among investors, leading to a sell-off in the stock.
• The positive outlook from William Blair maintaining a Buy rating for IDEXX Laboratories might not have been sufficient to offset broader market sentiments or specific concerns related to the company's performance metrics.
• The bearish movement in IDXX's stock price could also be influenced by broader market trends or sector-specific factors impacting investor sentiment towards healthcare and diagnostic companies.

IDXX Price Chart

IDXX Technical Analysis

IDXX News

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q1 2026 Earnings Call Transcript

IDEXX Laboratories reported strong financial results for Q1 2026, with revenue increasing 14% and EPS growing 15% to $3.47, exceeding expectations. The company raised its full-year revenue and EPS outlook, driven by robust performance in its companion animal diagnostics business and the continued success of innovations like inVue Dx and Cancer DX, despite a modest decline in U.S. clinical visits. Jay Mazelsky will transition to Executive Chair, with Mike Erickson succeeding him as CEO, emphasizing continued focus on diagnostics, software, AI, and global commercial expansion.

https://www.insidermonkey.com/blog/idexx-laboratories-inc-nasdaqidxx-q1-2026-earnings-call-transcript-1754778/

Jazz Pharmaceuticals (NASDAQ: JAZZ) swings to Q1 2026 profit on PRV sale

Jazz Pharmaceuticals reported a significant financial turnaround in Q1 2026, swinging to a net income of $293.1 million from a net loss of $92.5 million in the prior year, largely driven by a $122.8 million gain from the sale of a rare pediatric disease priority review voucher and robust revenue growth across its sleep, epilepsy, and oncology franchises. Total revenues climbed to $1,068.9 million, up from $897.8 million, with strong performances from Xywav, Epidiolex/Epidyolex, and oncology products like Zepzelca and the newly launched Modeyso and Ziihera. The company maintains significant liquidity with $2.9 billion in cash and investments, despite a total debt of $5.4 billion, and continues to invest heavily in R&D and strategic acquisitions to support its rare disease pipeline.

https://www.stocktitan.net/sec-filings/JAZZ/10-q-jazz-pharmaceuticals-plc-quarterly-earnings-report-b2e48beca527.html

William Blair Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating

William Blair has maintained its Buy rating for IDEXX Laboratories Inc (IDXX.US). This indicates a continued positive outlook on the company's stock performance from the analytical firm.

https://news.futunn.com/en/post/72541355/william-blair-maintains-idexx-laboratories-inc-idxxus-with-buy-rating

Cencora to Report Q2 Earnings: What's in Store for the Stock?

Cencora (COR) is set to report its fiscal second-quarter 2026 results on May 6. Analysts anticipate revenues of $80.76 billion, up 7% year-over-year, and earnings of $4.81 per share, representing an 8.8% improvement. While the company expects strong growth in specialty pharmaceuticals and its U.S. distribution business, the Zacks Model does not conclusively predict an earnings beat, with an Earnings ESP of -0.80% and a Zacks Rank #4 (Sell).

https://au.finance.yahoo.com/news/cencora-report-q2-earnings-whats-143200190.html

TransDigm's Q2 Earnings Surpass Estimates, Sales Increase Y/Y

TransDigm Group Incorporated (TDG) reported strong second-quarter fiscal 2026 results, surpassing analyst estimates for both earnings per share ($9.85 vs. $9.32) and sales ($2.54 billion vs. $2.42 billion). The company saw an 18% increase in sales year-over-year, driven by 11% organic growth, and has subsequently raised its full-year 2026 sales and EPS guidance. Despite a rise in interest expenses and debt, net income improved by 11.9%.

https://www.zacks.com/stock/news/2914902/transdigms-q2-earnings-surpass-estimates-sales-increase-yy

Trending Today

XRP ($XRP) Crypto Forecast: Up 5.3% Today

Aave ($AAVE) Crypto Forecast: Up 5.3% Today

IDEXX Laboratories Inc. Price History

03.10.2025 - IDXX Stock was up 1.5%

• Expectations are high for IDEXX Laboratories' upcoming release of Q3 earnings, with analysts predicting an increase in quarterly earnings compared to the previous year. This optimistic forecast likely played a role in the recent bullish movement in the stock.
• Over the past decade, IDXX has demonstrated impressive long-term performance, consistently outperforming the market and delivering substantial returns for investors. This consistent track record could be attracting more interest from investors.
• A Hershey analyst's shift in sentiment towards IDEXX Laboratories, no longer holding a bearish view, combined with other top analyst upgrades, may be bolstering investor confidence in the company's future prospects and contributing to the current bullish trend in the stock.

03.10.2025 - IDXX Stock was up 0.1%

• IDXX stock witnessed a notable upturn today after announcing impressive Q3 earnings that surpassed expectations, along with an optimistic future forecast.
• The company disclosed adjusted earnings of $3.22 per share, marking a 15% year-over-year increase and exceeding analyst estimates.
• Analysts had predicted earnings of $3.14 per share, underscoring confidence in the company's ability to deliver robust financial results.
• Top Wall Street analysts have upgraded their outlook on IDXX, reflecting an increasing bullish sentiment among investors.

05.02.2026 - IDXX Stock was down 5.1%

• IDXX experienced a bearish movement likely due to the overall challenges in the biotechnology sector as highlighted by an evaluation revision.
• The underperformance of a company and the broader sector may have raised concerns among investors, leading to a sell-off in IDXX.
• Market dynamics and performance challenges in the biotechnology sector could have contributed to the negative sentiment towards IDXX, resulting in the bearish movement.

05.02.2026 - IDXX Stock was down 5.3%

• The launch of the InVue product was expected to drive recurring revenue growth for IDEXX Laboratories. However, the market's reaction to significant stock selling by the CEO may have raised concerns among investors.
• The increased stake in IDXX by Victory Capital Management Inc. and New Age Alpha Advisors LLC could have been perceived positively. Still, substantial insider selling by the CEO may have overshadowed these moves, leading to a bearish sentiment.
• The CEO's sale of a significant amount of stock, mixed with missed EPS estimates in the recent earnings report, likely contributed to the bearish movement in IDXX's stock price today.
• The news of the stock falling below its 200-day moving average may have dampened the market sentiment towards IDXX, indicating a potential bearish signal and adding to the downward pressure on the stock price.

21.10.2025 - IDXX Stock was up 5.0%

• IDXX stock experienced a strong bullish movement today, breaking out above the 20-day moving average, indicating positive momentum.
• The news about Molina (MOH) securing a deal to serve Florida's Medicaid members is unrelated to IDXX's bullish movement.
• Investors may have reacted positively to the breakout above the moving average, signaling potential upside for IDXX in the near term.
• The breakout could be a result of increased investor confidence in the company's growth prospects and continued demand for its veterinary diagnostic solutions.

06.02.2026 - IDXX Stock was down 5.0%

• The introduction of InVue and the potential for recurring revenue growth highlighted IDXX's market strength. However, these advancements may not have fully countered the downward movement.
• Increased holdings by Victory Capital Management Inc. and New Age Alpha Advisors LLC reflect optimism in IDXX's future, indicating a favorable outlook.
• The stock's decline could be influenced by general market trends or profit-taking activities post recent performance, overshadowing the positive developments for IDXX.

02.01.2026 - IDXX Stock was down 1.7%

• Despite posting impressive Q4 earnings and revenue exceeding predictions, IDXX saw a downward trend in the market.
• A slight decline in stock price before the market opened may stem from heightened investor expectations, as the company emphasized robust pet health services and efficient cost control.
• Investors' varied responses could be linked to a marginal miss in earnings per share ($0.01) alongside revenue surpassing forecasts, leading to cautiousness among traders.
• IDXX's shares declining by 0.9% year-to-date, in contrast to the broader market's 1.4% gain (S&P 500), could have influenced the market downturn, with investors potentially anticipating more substantial growth despite the company's strong financial performance.

05.04.2026 - IDXX Stock was up 3.0%

• IDEXX Laboratories released its Q1 2026 financial results, with revenue reaching $1.14 billion, a 14.3% increase year-over-year, driven by its Companion Animal Group.
• The company's adjusted earnings per share matched market expectations, showing stability and investor confidence.
• Despite being removed from a specific list due to sector performance concerns, IDEXX's strong demand in pet diagnostics continues to drive revenue growth and positive market sentiment.
• The bullish movement could be attributed to the company's consistent financial performance and optimistic full-year revenue and earnings projections, indicating a promising outlook for investors.

06.04.2026 - IDXX Stock was down 0.4%

• Despite reporting strong financial results for Q1 2026 and raising its full-year outlook, concerns about the modest decline in U.S. clinical visits may have impacted future revenue growth potential for IDEXX Laboratories.
• The transition in leadership could have introduced uncertainty among investors, leading to a sell-off in the stock.
• The positive outlook from William Blair maintaining a Buy rating for IDEXX Laboratories might not have been sufficient to offset broader market sentiments or specific concerns related to the company's performance metrics.
• The bearish movement in IDXX's stock price could also be influenced by broader market trends or sector-specific factors impacting investor sentiment towards healthcare and diagnostic companies.